PR87571

CALCI, Italy, Jan. 12, 2021 /PRNewswire=KYODO JBN/ --

Toland joins Andrew Cleeland (Chairman of the Board, MMI) in developing the

field of robotic-assisted microsurgery

Medical Microinstruments (MMI) SpA[https://www.mmimicro.com/], a robotics

company dedicated to improving clinical outcomes for patients undergoing

microsurgery, announced today the hiring of Mark Toland as Chief Executive

Officer. He brings more than 25 years of experience in the medical device

industry and most recently served as President and CEO of Corindus, a vascular

robotics company that Siemens Healthineers acquired for $1.1 billion in 2019.

Following the CE mark of MMI's Symani Surgical System® in 2019 and successfully

completing the first human use cases in 2020, Toland will drive the company's

strategic direction from the developmental stage to broad commercialization.

"There is a tremendous need across healthcare to evolve treatment paradigms

from a predominantly manual model to one that leverages robotic technology,

data integration and AI to improve patient outcomes," said Toland. "The Symani

Surgical System offers an unprecedented level of precision for microsurgical

procedures that has the potential to significantly impact patient outcomes in

very complex procedures. I look forward to helping the company realize that

potential and working with a very talented and growing team at MMI."

The Symani Surgical System was used to successfully complete four

first-in-human surgical procedures in Florence, Italy. The cases included one

post-oncological reconstruction of the pharynx and three complex,

post-traumatic lower limb reconstructions, demonstrating the combined benefits

of tremor reduction and motion scaling (7-20x) with the system's NanoWrist®

instruments, the world's smallest wristed surgical instrumentation. The system

offers seven degrees of freedom and dexterity beyond the reach of human hands

to enhance free-flap reconstructions, replantations, congenital malformations,

peripheral nerve repairs and lymphatic surgery, which represent over one

million combined procedures annually in the U.S. and Europe.

"Mark's extensive experience in the medical device industry and particularly in

the field of robotics will play a pivotal role in MMI's continued growth and

impact on microsurgery," said Andrew Cleeland, the chairman of MMI's Board of

Directors. "We look forward to empowering surgeons around the world with the

most advanced technology that will make highly complex procedures more

reproducible and new procedures possible."  

Toland joined Corindus in 2016 and transformed the company into the industry

leader in vascular robotics with the only approved system for coronary,

peripheral and neurovascular indications.  Under Toland's leadership, the

company built advanced capabilities in automation and telerobotics, which

included the first ever remotely performed heart procedure in the world and

transcontinental pre-clinical studies using 5G technology. The Siemens

Healthineers acquisition of Corindus for $1.1 billion was the fifth largest

medical technology acquisition of 2019. Prior to Corindus, Mark served as

Senior Vice President of Boston Scientific, where he built the company's global

solutions business and led all aspects of the U.S. commercial team's cardiovascular

businesses, which represented approximately $4 billion in revenue.  

About MMI

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to

enhance surgical performance through the development of a robotic system that

enables surgeons to achieve better outcomes in microsurgery. The Symani

Surgical System combines proprietary innovations including the world's smallest

wristed microinstruments as well as tremor-reducing and motion-scaling

technologies. Together, these powerful capabilities allow more surgeons to

successfully perform microsurgery while expanding the field of supermicrosurgery.  

Logo - https://mma.prnewswire.com/media/1308712/MMI_SpA_Logo.jpg

www.matternow.com

SOURCE: MMI SpA